![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2020
Dreyling, Martin; Santoro, Armando; Mollica, Luigina; Leppä, Sirpa; Follows, George; Lenz, Georg; Kim, Won Seog; Nagler, Arnon; Dimou, Maria; Demeter, Judit; Özcan, Muhit; Kosinova, Marina; Bouabdallah, Krimo; Morschhauser, Franck; Stevens, Don A.; Trevarthen, David; Munoz, Javier; Rodrigues, Liana; Hiemeyer, Florian; Miriyala, Ashok; Garcia‐Vargas, Jose; Childs, Barrett H. und Zinzani, Pier Luigi
(2020):
Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study.
In: American Journal of Hematology, Bd. 95, Nr. 4: S. 362-371
[PDF, 1MB]
2017
Dreyling, Martin; Santoro, Armando; Mollica, Luigina; Leppä, Sirpa; Follows, George A.; Lenz, Georg; Kim, Won Seog; Nagler, Arnon; Panayiotidis, Panayiotis; Demeter, Judit; Özcan, Muhit; Kosinova, Marina; Bouabdallah, Krimo; Morschhauser, Franck; Stevens, Don A.; Trevarthen, David; Giurescu, Marius; Cupit, Lisa; Liu, Li; Köchert, Karl; Seidel, Henrik; Pena, Carol; Yin, Shuxin; Hiemeyer, Florian; Garcia-Vargas, Jose; Childs, Barrett H. und Zinzani, Pier Luigi
(2017):
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
In: Journal of Clinical Oncology, Bd. 35, Nr. 35: S. 3898-3910